ARCHIVES

Samuel Waksal Resigns From ImClone Following Unimpressive ASCO Presentation

This article is from The Cancer Letter archive.

Vol. 28 No. 21 | May 24, 2002

Download PDF Visit The Full Archive

Related Articles

Phase II Study Finds Dasatinib May Overcome ALL Resistance

May 25, 2007

Virus Cancer Program Includes “Some Of The Bes Basic Research Anywhere,” Moloney Says

January 9, 1976

Interferon “Hysteria” Prompts ASCO To Warn Against Expecting Immediate Benefits

June 20, 1980

DeVita: No Decision Yet On FCRF Award

July 17, 1987

NCI To Expand SPORE Grants Program to Increase Translational Research Funding

October 22, 1999

Quality of Care: ASCO Publishes “Top Five” Ways to Improve Cancer Care

November 1, 2013